<DOC>
	<DOCNO>NCT02262702</DOCNO>
	<brief_summary>The aim observational study compare use extend release paracetamol formulation standard paracetamol cohort Australian concessional patient osteoarthritis ( OA ) , assess difference prescribe pattern patient compliance .</brief_summary>
	<brief_title>Panadol Osteo Pharmaceuticals Benefit Scheme ( PBS ) Claims Cohort Study</brief_title>
	<detailed_description>This retrospective analysis physician prescribe data ( long-term concessional cohort Medicare Australia PBS claim dataset time period 2008-2011 ( 4 year ) compare use extended release paracetamol ( Panadol Osteo ) standard paracetamol 500mg cohort Australian concessional patient OA , ass difference prescribe pattern patient compliance .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Participants prescribe paracetamol product categorize concessional patient Participants new episode OA ( history OA paracetamol previous 12 month ) suffer chronic OA ( history OA paracetamol previous 12 month ) Participants Rheumatoid arthritis autoimmune inflammatory condition Participants receive follow antirheumatoid therapy : Immunimodulators methotrexate , leflunamide TNF blocker Participants receive treatment cancer pain</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>